AU2015204274B2 - Packaging material for a pharmaceutical product - Google Patents
Packaging material for a pharmaceutical product Download PDFInfo
- Publication number
- AU2015204274B2 AU2015204274B2 AU2015204274A AU2015204274A AU2015204274B2 AU 2015204274 B2 AU2015204274 B2 AU 2015204274B2 AU 2015204274 A AU2015204274 A AU 2015204274A AU 2015204274 A AU2015204274 A AU 2015204274A AU 2015204274 B2 AU2015204274 B2 AU 2015204274B2
- Authority
- AU
- Australia
- Prior art keywords
- packaging material
- coloured
- ink
- temperature
- marking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000005022 packaging material Substances 0.000 title claims abstract description 41
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 17
- 229940127557 pharmaceutical product Drugs 0.000 title abstract description 17
- 239000002221 antipyretic Substances 0.000 claims description 15
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 206010037660 Pyrexia Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 210000003813 thumb Anatomy 0.000 claims description 8
- 238000007639 printing Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 238000009512 pharmaceutical packaging Methods 0.000 claims description 4
- 210000003811 finger Anatomy 0.000 claims 2
- 239000000976 ink Substances 0.000 description 53
- 239000000463 material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 5
- 210000001061 forehead Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007650 screen-printing Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 238000007645 offset printing Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Packages (AREA)
- Details Of Rigid Or Semi-Rigid Containers (AREA)
Abstract
It is disclosed a packaging material for a pharmaceutical product. The packaging material comprises a coloured element which at about 380C 5 discolours partially, revealing a marking. The element is formed by a first portion forming the marking printed with conventional ink, and a second portion printed with thermochromic ink. The thermochromic ink is coloured below about 380C and becomes colourless when this temperature is reached or exceeded. The two portions are arranged so 10 that the first portion is invisible below about 38"C, but becomes visible when this temperature is reached or exceeded. 667418_1 (GHMarer) P971 AU1 LEANNE 2"11 FiQici. Fi 1
Description
06/07 2015 15:50 FAX ® 0006/0022 2015204274 06 Μ 2015 AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent
Applicant(s):
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Invention Title:
Packaging material for a pharmaceutical product
The following statement is a full description of this invention, including the best method for performing it known to me/us: RECEIVED TIME 6. JUL. 15:49
06/07 2015 15:50 FAX 00007/0022 2015204274 06 Μ 2015 1
PACKAGING MATERIAL FOR A PHARMACEUTICAL PRODUCT
Technical Field 5 The present invention relates to a packaging material for a pharmaceutical product, and to a method for producing such packaging material.
Background Art
The existence of pharmaceutical products capable of reducing the 10 fever is known. Said pharmaceutical products are also known under the name of antipyretics. Typical antipyretic drugs are paracetamol, acetylsalicylic acid, niflumic acid, nimesulide, ketoprofen, flurbiprofen and some derivatives thereof.
The existence of substances able to change colour at a 15 predetermined temperature is also known. Said substances are referred to as being "thermochromic". Generally, said substances form part of the category of liquid crystals.
During the last few decades numerous inks based on thermochromic substances have been investigated. These inks are called 20 ''thermochromic inks" and are used for silk-screen printing, flexographic printing, wet offset printing, lithographic printing and the like.
Some of these inks are coloured and change colour at a predetermined temperature. Other thermochromic inks are colourless and become coloured at a predetermined temperature. There are also 25 other inks which are coloured and become colourless at a predetermined temperature. US 2006/0241355 discloses a healthcare base including an area to receive a bottle that carries a health-related substance for the user to take. The bottle can be provided with a thermometer obtained with a 30 thermochromic paint. The temperature sensor includes a series of dots
0M7410_1 (OHMaOws) PM971AU.1 LEANNE RECEIVED TIME 6. JUL. .15:49
06/07 2015 15:50 FAX @0008/0022 2015204274 06 Μ 2015 2 arranged in an array with two axes. One axis is in one degree interval, and the other is in 0.2 degree interval. To use the thermometer, the user can hold the bottle against his/her forehead for a duration of time. Then, the user pulls the bottle away from the forehead to read the 5 temperature.
Summary of the invention
The inventor has noticed that the bottle with the thermometer disclosed by US 2006/0241355 is not comfortable and discrete to use. Indeed, for measuring the temperature, the patient/user should hold the 10 thermometer (i.e. the bottle) against a skin surface allowing each dot of the array to contact the patient's body (e.g. the forehead). However, holding a bottle against one's forehead is a pose that attracts attention and, in some situations (e.g. during travel, in the office, etc.), the patient/user may prefer not to perform it. 15 The inventor realised that it would be useful that a packaging of an antipyretic drug is equipped with an element capable of indicating to the patient/user, in a simpler and more discrete way, if she/he has a fever and therefore if she/he needs to be administered with the drug, even without having the precise measurement of her/his temperature. This 20 would be useful especially when the patient/user has not a thermometer at his disposal. Indeed, the patient/user may first use the package for verifying if she/he has a fever and then (for instance, when she/he goes home) use a thermometer for measuring his/her temperature. 25 Moreover, the inventor has noticed that hitherto the technology of thermochromic inks has not been widely adopted because it has a number of disadvantages of varying gravity depending on the characteristics of the thermochromic ink used.
In particular, the inventor realised that those thermochromic inks 30 which are coloured below their transition temperature and become
6667416J (CHMatters) MM71.AU.1 LfiANNE RECEIVED TIME 6. JUL. 15:49
06/07 2015 15:50 FAX 00009/0022 2015204274 06 Jul2015 3 colourless when said temperature is reached or exceeded are very disadvantageous. In fact, a marking printed with said ink disappears when the transition temperature is reached and this fact does not allow to send clear and accurate information or messages to the patient/user 5 as to whether or not said temperature is reached.
Accordingly, the inventor has addressed the problem of providing a packaging material for a pharmaceutical product which overcomes the aforesaid drawbacks.
In particular, the inventor has addressed the problem of providing a 10 packaging material for a pharmaceutical product which is able to indicate to a patient/user if she/he has a fever in a simpler and more discrete way with respect to the above .known solution and using a marking able to send clear messages to the patient/user as to whether or not a temperature is reached. 15 During the course of the present description and in the claims the expression: - "packaging material" is used to indicate any container, any label, any tag or any paper present in the packaging of a pharmaceutical product. The expression "packaging material" is used here to 20 indicate also any other type of material which accompanies a pharmaceutical product as distributed, presented and/or sold by the manufacturing company. Typical containers according to the present invention are cases, boxes, medicinal bottles, phials, blister packs, sachets and the like; 25 - "marking" is used to indicate any design, figure, letter of the alphabet, word, number, symbol, logo and any combination thereof. Typically, this marking indicates to the operator and/or the patient/user, a piece of information, a warning, a message or an alarm condition; 30
βββ?41β_1 (GHMaMws) P86S71.AU. I LEANNE RECEIVED TIME 6. JUL. 15:49 4 2015204274 18 Apr 2017 - "visible" is used to indicate that a marking can be clearly distinguished by the human eye when viewed by a normally attentive person. On the other hand, the term "invisible" is used to indicate that a marking cannot be clearly distinguished by the human eye 5 when viewed by a normally attentive person; - “about 38°C” indicates a temperature of 38°C±0.5°C; and - "conventional ink" is used to indicate an ink which, in a temperature range of between 30°C and 45°C, does not undergo changes in colour which are visible to the human eye when viewed by a normally 10 attentive person and which does not change from a colourless state to a coloured state or vice versa.
According to a first aspect thereof, the present invention relates to an antipyretic drug packaging material which can indicate a fever, the packaging having a coloured element which at about 38 °C 15 discolours partially, wherein: (a) said element is formed by a first portion, which forms a marking printed with a conventional ink, and by a second portion printed with a thermochromic ink, wherein said second portion of said coloured element surrounds and is situated alongside said first 20 portion on the same plane in a non-superimposed arrangement; (b) said thermochromic ink is coloured below about 38 °C and becomes colourless when said temperature is reached or exceeded; 25 (c) said first portion and second portion are arranged so that said first portion is invisible below about 38 °C and is visible when said temperature is reached or exceeded; (d) said packaging material is a box or a paper present in the packaging of the antipyretic drug; and 30 (e) the colour of the thermochromic ink is, below about 38°C, as 8960950_1 (GHMatters) P86971.AU.1 5 2015204274 18 Apr 2017 similar as possible to that of the conventional ink.
The abovementioned expression "discolours partially" with reference to the abovementioned coloured element is intended to mean that only the first portion, and not the second portion, discolours. 5 Preferably, said thermochromic ink is of the reversible type, i.e. it returns to the coloured state when the temperature falls below about 38°C.
In a first preferred embodiment of the packaging material according to the present invention, said second portion is superimposed on the 10 first portion.
In a second preferred embodiment of the packaging material according to the present invention, said first portion and second portion of said coloured element are situated alongside each other.
Preferably, when the first portion has spaces without conventional 15 ink, the second portion of the coloured element also covers said spaces.
Preferably, in this second embodiment, the colour of the thermochromic ink is, below about 38°C, quite similar to that of the conventional ink. 20 Even more preferably, the colour of the thermochromic ink is, below about 38°C, as similar as possible to that of the conventional ink.
Preferably, said pharmaceutical product is an antipyretic drug. According to a second aspect thereof, the present invention relates to a method of producing an antipyretic drug packaging material that can 25 indicate a fever, the packaging having a coloured element which at about 38°C discolours partially the production of said coloured element comprising the following steps: a) obtaining a packaging material; b) printing said marking on a first portion thereon using an ink of the 30 conventional type; 8960950 1 (GHMatters) P86971.AU.1 6 2015204274 18 Apr 2017 c) applying a thermochromic ink, which is coloured below the temperature of about 38°C, but becomes colourless when said temperature is reached, on a second portion surrounding and situated alongside the first portion on the same plane and in a non-5 superimposed arrangement so that said marking on the first portion is invisible below said temperature and is visible when said temperature is reached or exceeded, wherein said packaging material is a box or a paper present in the packaging of the antipyretic drug, wherein the colour of the 10 thermochromic ink is, below about 38°C, as similar as possible to that of the conventional ink.
Preferably the thermochromic ink is of the reversible type, i.e. it returns to the coloured state when the temperature falls below about 38°C. 15 In a first preferred embodiment of the method according to the present invention, said thermochromic ink forms a layer which is superimposed on the marking.
In a second preferred embodiment of the method according to the present invention, said thermochromic ink is applied so as to form a 20 layer which is situated alongside said marking.
Preferably, when the marking has spaces without conventional ink, said spaces are also covered by a layer of thermochromic ink.
Preferably, in this second embodiment, the colour of the thermochromic ink is, below about 38°C, quite similar to that of the 25 conventional ink with which the marking has been printed.
Even more preferably, the colour of the thermochromic ink is, below about 38°C, as similar as possible to that of the conventional ink with which the marking has been printed.
Brief description of the drawings 30 The present invention will now be further illustrated with reference to 8960950 1 (GHMatters) P86971.AU.1
06/07 2015 15:51 FAX 00013/0022 2015204274 06 Μ 2015 7 the accompanying drawings provided by way of a non-limiting example in which:
Figure 1 is a schematic perspective view of a packaging material, according to a first preferred embodiment of the present invention, 5 in which the temperature of the coloured element is lower than about 38°C;
Figure 2 is a schematic view of the material according to Fig. 1, in which a feverish patient/user presses his thumb onto the coloured element; 10 - Figure 3 is a schematic view of the material according to Fig. 1 immediately after the patient/user has moved his thumb away from the coloured element;
Figure 4 is a schematic perspective view of a packaging material according to a second preferred embodiment of the present 15 invention, in which the temperature of the coloured element is lower than about 38°C;
Figure 5 is a schematic view of the material according to Fig.4, in which the temperature of the coloured element is equal to or greater than about 38°C. 20 Detailed description of preferred embodiments of the invention
Figures 1-3 show a packaging material 1 according to a first preferred embodiment of the present invention. The packaging material 1 is a parallelepiped-shaped box containing a pharmaceutical product. Preferably, said pharmaceutical product is a drug the administration of 25 which is useful or necessary during feverishness. More preferably, said pharmaceutical product is an antipyretic drug.
As already stated, this type of packaging material is not limiting, in that the packaging material may be a label, tag, phial, sachet, blister pack, medicinal bottle, case, powder sachet, or any other packaging 30 material commonly used in the pharmaceutical sector. The packaging
6667418..1 (GHMaltere) P86971.AU.1 LEANNE
RECEIVED TIME 6. JUL. 15:49 06/07 2015 15:51 FAX @0014/0022 2015204274 06 Μ 2015 8 material 1 can also be any other type of material which accompanies a pharmaceutical product as distributed, presented and/or sold by the manufacturing company.
According to preferred embodiments of the present invention, a 5 coloured element 2 is associated with the packaging material 1.
This coloured element 2 is advantageously arranged on an outer surface of an opening/closing flap 3 of the box 1 so that it is easier to hold it for a feverish patient/user who has to exert a certain pressure with his thumb onto the coloured element (Fig.2). 10 Preferably, this coloured element 2 comprises a conventional red ink and a thermochromic ink which changes from red to a colourless state at about 38°C. Preferably, the change of colour of said thermochromic ink is reversible since its colour becomes red again when the temperature falls below said temperature. 15 More particularly, said conventional ink preferably forms a marking 2' consisting of a picture of a painstricken face and said thermochromic ink forms a layer 2" superimposed on the marking 2'.
When the temperature of the element 2 is less than about 38°C, the layer 2" of said thermochromic ink fully covers and renders the marking 20 2'invisible (Figure 1).
However, when the temperature of the element 2 is equal to, or greater than, 38°C the layer 2" of said thermochromic ink preferably becomes colourless and renders said marking 2' visible (Figure 3).
Therefore, the appearance of the marking 2’ informs the patient/user 25 that he has really a fever and that he needs to be administered with the antipyretic drug contained in the box 1.
Alternatively, in place of consisting of a picture of a painstricken face, the marking 2’ can consist of any other picture, symbol or word capable of instructing the patient/user that his body temperature is of about 30 38°C. For instance, the marking 2’ may simply consist of the symbol eSB74iej (GHMatters) Ρββ871·Αυ.1 LEANN£ RECEIVED TIME 6. JUL. 15:49
06/07 2015 15:51 FAX @0015/0022 2015204274 06 Μ 2015 9 “38°C".
Figures 4 and 5 show a packaging material 11 according to a second preferred embodiment of the present invention.
This packaging material 11 differs from that of Fig.1-3 primarily in 5 that the thermochromic ink forms a layer 12" which surrounds and is situated alongside the marking 12' and fills the spaces without conventional ink (i.e. eyes and mouth) so as to form the coloured element 12 where the marking 12' is invisible as long as the temperature of the packaging material 1 is less than said 10 predetermined temperature (Figure 4).
In the embodiment of Fig.4 a thermochromic ink was used whose colour was, below about 38°C, substantially equal to that of the conventional ink with which the marking 12’ had been printed so as to substantially render the marking 12’ invisible. 15 Finally, Fig. 5 shows the marking 12’ as it appears after the thumb of a feverish patient has pressed the element 12.
Examples of suitable thermochromic inks according to preferred embodiments of the present invention are those described in US 4,385,844. 20 Other suitable thermochromic inks according to preferred embodiments of the present invention are the offset inks DYNACOLOR™ produced by the company C.T.I (Chromatic Technologies Incorporated), Colorado Springs, U.S.A. Said inks are described by the patents US 5,591,255 and 5,997,849. 25 Other suitable thermochromic inks according to preferred embodiments of the present invention are the inks produced by the company SICPA SA, Prilly, Switzerland.
According to preferred embodiments of the present invention, the printing techniques are silk-screen printing and flexographic printing. 30 Although the packaging material of preferred embodiments of the 6ββ741β_1 (GHMatters) PM971 AU.1 ΙΕΛΝΝΕ RECEIVED TIME 6. JUL. 15:49
06/07 2015 15:51 FAX @0016/0022 2015204274 06 Μ 2015 10 present invention has been illustrated further above with particular reference to a packaging for an antipyretic drug, it is clear that it can also advantageously be used in connection with any other pharmaceutical product to be administered during feverishness. 5 It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
In the claims which follow and in the preceding description of the 10 invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise" or variations such as "comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the 15 invention.
6667410J (SHMaltere) P88971.AU.1 LEANNE RECEIVED TIME 6. JUL. -15:49
Claims (12)
1. An antipyretic drug packaging material which can indicate a fever, the packaging having a coloured element which at about 38 °C discolours partially wherein: (a) said element is formed by a first portion, which forms a marking printed with a conventional ink, and by a second portion printed with a thermochromic ink, wherein said second portion of said coloured element surrounds and is situated alongside said first portion on the same plane in a non-superimposed arrangement; (b) said thermochromic ink is coloured below about 38 °C and becomes colourless when said temperature is reached or exceeded; (c) said first portion and second portion are arranged so that said first portion is invisible below about 38 °C and is visible when said temperature is reached or exceeded; (d) said packaging material is a box or a paper present in the packaging of the antipyretic drug; and (e) the colour of the thermochromic ink is, below about 38°C, as similar as possible to that of the conventional ink.
2. The packaging material according to Claim 1, wherein the thermochromic ink is of the reversible type.
3. The packaging material according to either Claim 1 or 2, wherein, when the first portion has spaces without conventional ink, the second portion of the coloured element also covers said spaces.
4. The packaging material according to any one of the preceding claims, wherein said coloured element is arranged on a surface of an opening/closing flap of the packaging material.
5. The packaging material according any one of the preceding claims, wherein said coloured element is configured for being pressed by a thumb of a user.
6. The packaging material according to any one of Claims 1 to 4, wherein said coloured element is configured for being pressed between a thumb and another finger of a user.
7. A method of producing an antipyretic drug packaging material which can indicate a fever, the packaging having a coloured element which at about 38°C discolours partially, the production of said coloured element comprising the following steps: a) obtaining a packaging material; b) printing a marking on a first portion thereon using an ink of the conventional type; c) applying a thermochromic ink, which is coloured below the temperature of about 38°C, but becomes colourless when said temperature is reached, on a second portion surrounding and situated alongside the first portion on the same plane and in a non-superimposed arrangement so that said marking on the first portion is invisible below said temperature and is visible when said temperature is reached or exceeded, wherein said packaging material is a box or a paper present in the packaging of the antipyretic drug, wherein the colour of the thermochromic ink is, below about 38°C, as similar as possible to that of the conventional ink.
8. The method according to Claim 7, wherein the thermochromic ink is of the reversible type.
9. The method according to either Claim 7 or 8, wherein, when the marking has spaces without conventional ink, said spaces are also covered by a layer of thermochromic ink.
10. The method according to any one of Claims 7 to 9, wherein said coloured element is arranged on a surface of an opening/closing flap of the packaging material.
11. The method according to any one of Claims 7 to 10, wherein said coloured element is configured for being pressed by a thumb of a user.
12. The method according to any one of Claims 7 to 10, wherein said coloured element is configured for being pressed between a thumb and another finger of a user.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015204274A AU2015204274B2 (en) | 2008-11-25 | 2015-07-06 | Packaging material for a pharmaceutical product |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425748 | 2008-11-25 | ||
| EP08425748.4 | 2008-11-25 | ||
| AU2009319100A AU2009319100A1 (en) | 2008-11-25 | 2009-11-13 | Packaging material for a pharmaceutical product |
| PCT/EP2009/065113 WO2010060813A1 (en) | 2008-11-25 | 2009-11-13 | Packaging material for a pharmaceutical product |
| AU2015204274A AU2015204274B2 (en) | 2008-11-25 | 2015-07-06 | Packaging material for a pharmaceutical product |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009319100A Division AU2009319100A1 (en) | 2008-11-25 | 2009-11-13 | Packaging material for a pharmaceutical product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015204274A1 AU2015204274A1 (en) | 2015-08-13 |
| AU2015204274B2 true AU2015204274B2 (en) | 2017-05-11 |
Family
ID=53836266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015204274A Ceased AU2015204274B2 (en) | 2008-11-25 | 2015-07-06 | Packaging material for a pharmaceutical product |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2015204274B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647225A1 (en) * | 2006-04-04 | 2007-10-18 | Giesecke & Devrient Gmbh | Security element |
-
2015
- 2015-07-06 AU AU2015204274A patent/AU2015204274B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647225A1 (en) * | 2006-04-04 | 2007-10-18 | Giesecke & Devrient Gmbh | Security element |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015204274A1 (en) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102224013B (en) | Packaging material with coloured element which at predetermined temperature discolours partially, revealing marking, and method for producing this material | |
| US8754006B2 (en) | Packaging material for a pharmaceutical product having a coloured element which at a predetermined temperature discolours partially, revealing a marking, and method for producing this material | |
| JP2002527720A (en) | LCD thermometer | |
| US20090206080A1 (en) | Universal Lids and Methods for Making and Using the Same | |
| AU2015204274B2 (en) | Packaging material for a pharmaceutical product | |
| KR20120004022A (en) | Sticky Temperature Indicator | |
| US20080184927A1 (en) | Container cap for assuring quality | |
| HK1160921A (en) | Packaging material for a pharmaceutical product | |
| HK1160921B (en) | Packaging material for a pharmaceutical product | |
| CN201324380Y (en) | Container capable of displaying temperature | |
| AU2015204272B2 (en) | Packaging material for a pharmaceutical product and method for producing this material | |
| JP4699015B2 (en) | Pharmaceutical time indicator | |
| KR20090111059A (en) | Container displaying temperature of contents and manufacturing method thereof | |
| KR20250000147A (en) | ondo allim jong-ikeob-ui ttukkeong | |
| KR20200064366A (en) | Safe Sleeve Based Temperature Reminder Paper Cup | |
| KR20200059844A (en) | Safe Sleeve Based Temperature Reminder Paper Cup | |
| KR20200062978A (en) | a cup that colors temperature | |
| ES1073918U (en) | Adhesive label with thermosensitive temperature indicator band and microencapsulated liquid crystals contact thermography adaptively specified colorimetry. (Machine-translation by Google Translate, not legally binding) | |
| KR20190119286A (en) | Temperature measured according to color | |
| TWM338658U (en) | Feeding bottle capable of detecting temperature |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |